Dose-Reduced IPV Vaccine via TRIS Buffer Inactivation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The high production costs and limited availability of Inactivated Polio Vaccine (IPV) pose challenges for global demand, especially in low and middle-income countries, due to the need for more virus per dose, additional processing steps, and antigen loss during production, making it unaffordable and scarce.
Innovation Solution
A dose-reduced IPV composition using TRIS buffer for formaldehyde inactivation and adsorption on aluminium hydroxide, which minimizes antigen loss and allows for a significant reduction in the amount of IPV antigen required, thereby reducing production costs and increasing vaccine availability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional IPV production methods are used, then vaccine safety and immunogenicity are ensured, but production costs are high and vaccine availability is limited
Solution Approach 1:
The patent changes the chemical parameter of the buffer system from phosphate-based to TRIS-based, which fundamentally alters the inactivation kinetics and antigen stability characteristics. This parameter change enables more efficient inactivation with better antigen recovery, directly addressing the contradiction between safety (complete inactivation) and productivity (antigen retention for vaccine production).
Solution Approach 2:
The patent replaces the traditional phosphate buffer chemical system with a TRIS buffer system, substituting one chemical mechanism for another more effective one. This substitution achieves superior inactivation efficiency and antigen stability, resolving the contradiction between ensuring complete viral inactivation (safety) and minimizing antigen loss (productivity).
2Reliability
If conventional IPV production methods are used, then immunogenicity is maintained, but antigen loss during processing is significant
Solution Approach 1:
By changing the buffer pH and composition parameters to TRIS-based systems, the patent optimizes the chemical environment during inactivation to better preserve antigen structure and function. This parameter optimization reduces antigen loss while maintaining the immunogenic properties necessary for vaccine effectiveness.
3Reliability
If standard IPV dosing is used, then protective immunity is achieved, but production costs are prohibitively high for low and middle-income countries
Solution Approach 1:
The patent's parameter changes in the inactivation process result in higher antigen recovery rates, which directly reduces the amount of starting material needed and lowers production costs. This makes the vaccine more economically viable for low and middle-income countries while maintaining immunogenicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves an 8-fold dose reduction for Sabin Type I and 3-fold dose reduction for Sabin Type III IPV, enhancing vaccine supply and affordability while maintaining immunogenicity, making it more accessible to developing countries.
Implementation Method 1
formaldehyde inactivation of poliovirus particles
Implementation Method 2
adsorption on aluminium hydroxide
Data Source
AI summary
The present invention is directed to improved methods of Enterovirus inactivation by formaldehyde in presence of tromethamine buffer resulting in maximum recovery of D-antigen. Subsequent adsorption of said sIPV on aluminium hydroxide provides significantly dose reduced sIPV compositions.